Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
JNJ-54861911, 10 mg
DRUG
2 trials
Sponsors
Janssen Pharmaceutical K.K.
, Janssen Research & Development, LLC
Conditions
Alzheimer Disease
Alzheimer's Disease
Phase 1
Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia
Completed
NCT02360657
Janssen Pharmaceutical K.K.
Alzheimer's Disease
Start: 2015-02-16
End: 2015-09-08
Updated: 2019-02-04
Phase 2
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum
Terminated
NCT02406027
Janssen Research & Development, LLC
Alzheimer Disease
Start: 2015-07-02
End: 2018-06-28
Updated: 2025-04-29
Related Papers
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
2020-05-14
80 citations
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
Alzheimer s Research & Therapy
2018-08-22
106 citations